Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024
Shots:
- The P-II trial assessed safety & efficacy of islatravir (2mg) + lenacapavir (300mg, oral, QW) in virologically suppressed HIV adults (n=104, median age: 40yrs.) on Biktarvy or they may continue daily Biktarvy
- Study showed a viral suppression (HIV-1 RNA <50 copies/mL) rates of 94.2% with the combination (none of them had a viral load of ≥50 copies/mL) and 94.2% vs 92.3% in those who switched to the regimen vs continued Biktarvy at 48wks. The primary data from wk.24 were presented earlier at CROI 2024
- The islatravir and lenacapavir regimen, as a fixed-dose, is also being investigated under two P-III trials (NCT06630286 & NCT06630299) in virologically suppressed people with HIV
Ref: Merck | Image: Merck & Gilead
Related News:- Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
